The more I mull over the B-OM results, the more I like them. B has proven itself in B-ABSSII, B-UC and now the OM indication. If I were a large pharma, I would be very interested in taking these drugs through the phase III process to commercialization since there is every indication that they do what the preclinical work suggested and they appear to be very safe as well. Once the secondary endpoint data is in, significant news could come at anytime....IMHO